VRCI
vs
F
FTSE All Share Index
VRCI
Over the past 12 months, VRCI has outperformed FTSE All Share Index, delivering a return of -78% compared to the FTSE All Share Index's 0% growth.
Stocks Performance
VRCI vs FTSE All Share Index
Performance Gap
VRCI vs FTSE All Share Index
Performance By Year
VRCI vs FTSE All Share Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Verici Dx Plc
Glance View
Verici Dx Plc operates as a developer of advanced clinical diagnostics in organ transplant. The company is headquartered in Franklin, Tennessee and currently employs 8 full-time employees. The company went IPO on 2020-11-03. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The firm's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The firm develops tests to understand how a patient is responding to organ transplants. The firm's products include Clarava and Tuteva. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including sub-clinical rejection. The firm's subsidiary is Verici Dx Inc.
